Alpine Immune Sciences Future Growth
Future criteria checks 2/6
Alpine Immune Sciences's earnings are forecast to decline at 13.6% per annum while its annual revenue is expected to grow at 28.5% per year. EPS is expected to decline by 10.3% per annum. Return on equity is forecast to be -106.3% in 3 years.
Key information
-13.6%
Earnings growth rate
-10.3%
EPS growth rate
| Biotechs earnings growth | 20.6% |
| Revenue growth rate | 28.5% |
| Future return on equity | -106.3% |
| Analyst coverage | Good |
| Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Apr 11Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts
Mar 21
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug
Mar 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up
Feb 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up
Dec 19We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
May 11Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Alpine Immune Sciences drops 13% after hours on $100M stock offering
Sep 20Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Alpine: Rest Before Rallying Again
Apr 25Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right
Jun 03Alpine Immune Sciences files for $150M mixed shelf offering
May 26Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9 | -150 | -173 | -150 | 7 |
| 12/31/2025 | 19 | -113 | -140 | -113 | 8 |
| 12/31/2024 | 16 | -101 | -96 | -91 | 9 |
| 12/31/2023 | 59 | -32 | -79 | -79 | N/A |
| 9/30/2023 | 31 | -57 | -77 | -77 | N/A |
| 6/30/2023 | 29 | -59 | -78 | -77 | N/A |
| 3/31/2023 | 26 | -64 | -76 | -75 | N/A |
| 12/31/2022 | 30 | -58 | -44 | -44 | N/A |
| 9/30/2022 | 32 | -54 | -42 | -42 | N/A |
| 6/30/2022 | 32 | -54 | 4 | 5 | N/A |
| 3/31/2022 | 34 | -47 | 6 | 6 | N/A |
| 12/31/2021 | 23 | -50 | -15 | -15 | N/A |
| 9/30/2021 | 25 | -42 | -10 | -10 | N/A |
| 6/30/2021 | 18 | -34 | -46 | -45 | N/A |
| 3/31/2021 | 11 | -33 | 23 | 24 | N/A |
| 12/31/2020 | 9 | -28 | 29 | 30 | N/A |
| 9/30/2020 | 5 | -28 | 33 | 34 | N/A |
| 6/30/2020 | 3 | -33 | 28 | 29 | N/A |
| 3/31/2020 | 3 | -35 | -35 | -34 | N/A |
| 12/31/2019 | 2 | -42 | -36 | -35 | N/A |
| 9/30/2019 | 1 | -47 | -39 | -39 | N/A |
| 6/30/2019 | 1 | -48 | -36 | -36 | N/A |
| 3/31/2019 | 0 | -44 | -35 | -35 | N/A |
| 12/31/2018 | 1 | -36 | -29 | -28 | N/A |
| 9/30/2018 | 1 | -30 | -25 | -25 | N/A |
| 6/30/2018 | 1 | -15 | -23 | -22 | N/A |
| 3/31/2018 | 1 | -11 | -19 | -19 | N/A |
| 12/31/2017 | 2 | -8 | -17 | -17 | N/A |
| 9/30/2017 | 2 | -5 | N/A | -13 | N/A |
| 6/30/2017 | 3 | -7 | N/A | -9 | N/A |
| 3/31/2017 | 3 | -3 | N/A | -6 | N/A |
| 12/31/2016 | 3 | -1 | N/A | -4 | N/A |
| 12/31/2015 | 0 | 0 | N/A | 5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALPN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALPN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALPN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALPN's revenue (28.5% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: ALPN's revenue (28.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALPN is forecast to be unprofitable in 3 years.